Clorox Stock (NYSE:CLX), Trade Ideas

Clorox

Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.

News

Small Cap

Markets

Trading Ideas

CHEF

VITL

The Clorox Company (NYSE: CLX) stock is doing well on the bourses, thanks to its robust strategic efforts. The company has been gaining from pricing and cost-saving initiatives for a while now.

Here&#39;s Why Clorox&#39;s (CLX) Strategic Efforts Appear Good

Wall Street

Analyst Color

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Analyst Ratings

Tech

ETFs

AMZN

CHTR

DECK

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

LBRDA

SAIA

iShares Trust Barclays 20+ Year Treasury Bond Fund

XLRE

Select Sector SPDR-Consumer Discretionary

US stock market sees fourth consecutive week of gains, driven by strong tech earnings and labor market. Total market value surpasses $12.9 trillion.

Stocks Notch 4th Straight Positive Week Driven By Tech, Meta Shines, Bonds Tank On Hot Jobs Data: What&#39;s Driving Markets Friday?

Penny Stocks

Intraday Update

Movers

AAOI

AAPL

AGRI

ATUS

BRTX

CCTG

CING

CISS

CVKD

EXPO

FBLG

GSX Techedu Inc. American Depositary Shares

GOTU

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HSAI

Intelligent Bio Solutions Inc. - Common Stock

INBS

KOPN

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MARK

MCAF

MDVL

MINM

NUZE

PGRU

RCRT

REVB

ROMA

SHOP

TEAM

TRUG

TYRA

Shares of Skechers U.S.A., Inc.  (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.

Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Clorox Co

Calix Ltd

COLLEXIS HOLDINGS INC by Collexis Holdings, Inc.

Collexis Holdings Inc

<p>Deutsche Bank  analyst Stephen Powers   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Hold and lowers the price target from $155 to $151.</p>


Price Target

Deutsche Bank Maintains Hold on Clorox, Lowers Price Target to $151

<p>DA Davidson  analyst Linda Bolton Weiser   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and maintains $162 price target.</p>


DA Davidson Maintains Neutral on Clorox, Maintains $162 Price Target

<p>Across the recent three months, 9 analysts have shared their insights on Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Clorox, presenting an average target of $153.89, a high estimate of $170.00, and a low estimate of $136.00. This current average represents a 1.04% decrease from the previous average price target of $155.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713279655_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Clorox is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$136.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$162.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clorox. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clorox compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Clorox's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Clorox analyst ratings.</strong></a></p>
<h2>Discovering Clorox: A Closer Look</h2>
<p>Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.</p>
<h3>Breaking Down Clorox's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Clorox displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>16.04%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Clorox's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.67%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clorox's ROE excels beyond industry benchmarks, reaching <strong>1162.5%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Clorox's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.56%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Clorox's debt-to-equity ratio surpasses industry norms, standing at <strong>59.04</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 9 Analyst Evaluations For Clorox

<p>Citigroup  analyst Wendy Nicholson   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $165 to $155.</p>


Citigroup Maintains Neutral on Clorox, Lowers Price Target to $155

<p>Barclays  analyst Lauren Lieberman   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and lowers the price target from $148 to $136.</p>


Barclays Maintains Underweight on Clorox, Lowers Price Target to $136

<p><strong>The Clorox Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>)&nbsp;stock is doing well on the bourses, thanks to its robust strategic efforts. The company has been gaining from pricing and cost-saving initiatives for a while now. Its latest and integrated IGNITE strategy focuses on the expansion of the key elements under the 2020 Strategy to pace up innovation across each area of the business.<br />
Shares of this producer, marketer and seller of consumer products have increased 18.6% in the past six months compared with the industry&#39;s 10.1% upside. A Growth Score of B further adds strength to this current Zacks Rank #3 (Hold) company.</p>
<h3>Let&#39;s Delve Deeper</h3>
<p>Clorox&#39;s robust pricing and cost-saving initiatives offset elevated manufacturing and logistic costs. This led to a gross margin expansion of 730 basis points (bps) year over year during the second quarter of fiscal 2024. This marked the fifth consecutive quarter of gross margin expansion on the back of pricing and cost savings, somewhat offset by adverse foreign currency fluctuations. For fiscal 2024, the gross margin is projected to expand 200 bps year over year.<br />
The company is on track with the IGNITE strategy. This strategy encompasses the long-term financial targets of achieving net sales growth of 3-5%, EBIT margin expansion of 25-50 bps and free cash flow generation of 11-13% of sales.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fb/64617.jpg?v=579983060" /><br />
Image Source: Zacks Investment Research</p>
<p>Management had announced a streamlined operating model to create a faster, simpler company through the Reimagine Work under its IGNITE strategy. The operating model helps increase efficiency and transforms the company&#39;s operations in the areas of the supply chain, digital commerce, innovation and brand building over the long term.<br />
The streamlined operating model is expected to enhance the company&#39;s ability to respond more quickly to changing consumer behaviors, innovate faster and increase cash flow as a result of cost savings that will be generated primarily in the areas of selling and administration, supply chain, marketing, and research and development. Once fully implemented, the company expects cost savings of approximately $75 million to $100 million annually.<br />
Clorox had announced plans to invest $500 million in the next few years in transformative technologies and processes. The investments began in the first quarter of fiscal 2022 and include the replacement of the company&#39;s enterprise resource planning system, its transition to a cloud-based platform and the implementation of a suite of other digital technologies. Of the $500-million investment, the company will record 55% as incremental operating costs within selling and administrative expenses to be adjusted from the reported earnings per share.</p>
<h3>Stocks to Consider</h3>
<p><strong>The Chef&#39;s Warehouse</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chef#NASDAQ">CHEF</a>), which engages in the distribution of specialty food products, currently carries a Zacks Rank #2 (Buy). CHEF has a trailing four-quarter earnings surprise of 3.2%, on average.<br />
The Zacks Consensus Estimate for The Chef&#39;s Warehouse&#39;s current fiscal year sales and earnings suggests growth of 8.7% and 4.7%, respectively, from the year-ago reported numbers.<br />
<strong>Vital Farms Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vitl#NASDAQ">VITL</a>) offers a range of produced pasture-raised foods. It currently carries a Zacks Rank of 2. VITL has a trailing four-quarter average earnings surprise of 155.4%.<br />
The Zacks Consensus Estimate for Vital Farms&#39; current financial-year sales and earnings suggests growth of 18.6% and 35.6%, respectively, from the year-ago reported numbers.<br />
<strong>Utz Brands Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/utz#NYSE">UTZ</a>), which manufactures a diverse portfolio of salty snacks, currently carries a Zacks Rank of 2. UTZ has a trailing four-quarter earnings surprise of 2.6%, on average.<br />
The Zacks Consensus Estimate for Utz Brands&#39; current financial-year earnings suggests growth of 15.8% from the year-ago reported numbers.</p>
<p><a href="https://www.zacks.com/stock/news/2252474/here-s-why-clorox-s-clx-strategic-efforts-appear-good?cid=CS-BENZ-FT-analyst_blog|rank_focused-2252474">To read this article on Zacks.com click here.</a></p>


Here's Why Clorox's (CLX) Strategic Efforts Appear Good

WIIM

Clorox shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $170 to $165.

<p>Citigroup  analyst Wendy Nicholson   downgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Buy to Neutral and lowers the price target from $170 to $165.</p>


Downgrades

Citigroup Downgrades Clorox to Neutral, Lowers Price Target to $165

<p>Morgan Stanley  analyst Dara Mohsenian   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and maintains $160 price target.</p>


Morgan Stanley Maintains Equal-Weight on Clorox, Maintains $160 Price Target

<p>In the last three months, 6 analysts have published ratings on Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Clorox, presenting an average target of $147.83, a high estimate of $170.00, and a low estimate of $118.00. Surpassing the previous average price target of $135.00, the current average has increased by 9.5%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711461621_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Clorox is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$162.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clorox. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clorox compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Clorox's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Clorox's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Clorox analyst ratings.</strong></a></p>
<h2>About Clorox</h2>
<p>Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.</p>
<h3>Clorox's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Clorox's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>16.04%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Clorox's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.67%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clorox's ROE excels beyond industry benchmarks, reaching <strong>1162.5%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.56%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>59.04</strong>, caution is advised due to increased financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Clorox Stock: Analyst Perspectives (6 Ratings)

<p>Jefferies  analyst Kaumil Gajrawala   upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Underperform to Hold and announces $145 price target.</p>


Upgrades

Jefferies Upgrades Clorox to Hold, Announces $145 Price Target

<p>Ratings for Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $148.67, a high estimate of $170.00, and a low estimate of $118.00. Witnessing a positive shift, the current average has risen by 13.27% from the previous average price target of $131.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709305218_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Clorox among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$162.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clorox. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Clorox compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Clorox's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Clorox's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Clorox analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Clorox</h2>
<p>Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.</p>
<h3>Clorox: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Clorox displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>16.04%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Clorox's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.67%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clorox's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1162.5%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.56%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>59.04</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 6 Analysts Discuss Clorox Stock

<p>Goldman Sachs  analyst Bonnie Herzog   reinstates Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Sell and announces $140 price target.</p>


Initiation

Goldman Sachs Reinstates Sell on Clorox, Announces $140 Price Target

<p>DA Davidson  analyst Linda Bolton Weiser   downgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Buy to Neutral and announces $162 price target.</p>


DA Davidson Downgrades Clorox to Neutral, Announces $162 Price Target

<p>The U.S. stock market, as gauged by the S&amp;P 500 index, is on track to record its fourth consecutive week of gains, marking its 13th positive week out <a href="https://www.benzinga.com/markets">of the last 14.</a></p>
<p>The broad gains seen across major U.S. stock averages on Friday have been fueled by major tech earnings surpassing expectations and a labor market showing more strength than predicted in January, maintaining high expectations for robust consumer spending in the near future.</p>
<p>The S&amp;P 500 was up 0.8% reaching fresh record highs as of midday trading in New York. </p>
<p><strong>Meta Platforms Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) skyrocketed over 22% following an impressive earnings report and optimistic guidance for 2024. <strong>Amazon.com Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) soared more than 8% after reporting a 14% jump in revenue and record-breaking profits. </p>
<p>Collectively, the market value of the Magnificent Seven has hit $12.9 trillion, surpassing the combined worth of economies such as Germany, Japan, and India. </p>
<p>The January jobs report showcased remarkable job growth, with payrolls increasing by 353,000—nearly twice the anticipated 180,000. Additionally, wages rose more than expected, challenging the forecasts <a href="https://www.benzinga.com/news/large-cap/24/02/36908814/us-economy-adds-353-000-payrolls-in-january-monster-job-growth-well-above-expectations-destroys-fe">for interest rate cuts.</a></p>
<p>Traders now believe a March cut is off the table, and they are also reducing their expectations for a cut in May. As a result, the total number of rate cuts anticipated for 2024 has decreased from six to five.</p>
<p>Bonds took a hit, as yields rose substantially across the curve. The popular <strong>iShares 20+ Year Treasury Bond </strong>ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) tanked 2.5%. </p>
<h2 class="wp-block-heading">Friday's Performance In Major Indices, ETFs</h2>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<thead>
<tr>
<th><strong>Index</strong></th>
<th><strong>Price</strong></th>
<th><strong>Change (%)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasdaq 100</td>
<td>17,634.97</td>
<td>+1.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>4,954.20</td>
<td>+1.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,589.48</td>
<td>+0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>193.54</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>The <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.9% higher to $493.69, the <strong>SPDR Dow Jones Industrial Average</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.2% to $385.86 and the tech-heavy <strong>Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.7% to $429.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. </p>
<p>Sector-wise, the <strong>Communication Service SPDR Select Sector Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) rallied, up 3.8%, followed by the <strong>Consumer Discretionary</strong> <strong>SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) up 1.5%.</p>
<p>Sector laggards were the <strong>Real Estate SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>), down 1.9%, and the <strong>Utilities</strong> <strong>SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>), down 2%. </p>
<h2 class="wp-block-heading">Friday&#8217;s Stock Movers</h2>
<ul>
<li><strong>Deckers Outdoor Corporation </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) rose 16% after reporting better-than-expected results. </li>
<li><strong>Charter Communications, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) fell over 15% after missing earnings. </li>
<li>Other companies reacting to earnings <strong> Saia, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 12%, <strong>The Cigna Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), up 5.6%, <strong>Gen Digital Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), down 13%, <strong>Royal Caribbean Cruises Ltd. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), down 4%, <strong>Clorox Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), up 5.5%. </li>
</ul>
<p>Read now: <em><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36912911/6-apple-analysts-size-up-q1-results-iphone-sales-major-step-in-the-right-direction-">6 Apple Analysts Size Up Q1 Results, iPhone Sales: &#8216;Major Step In The Right Direction,&#8217; &#8216;Some Good And Bad News&#8217;</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Stocks Notch 4th Straight Positive Week Driven By Tech, Meta Shines, Bonds Tank On Hot Jobs Data: What's Driving Markets Friday?

<p>UBS  analyst Peter Grom   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $145 to $170.</p>


UBS Maintains Neutral on Clorox, Raises Price Target to $170

<p>Shares of <strong>Skechers U.S.A., Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/skx#NYSE">SKX</a>) shares fell during Friday&rsquo;s session after the company reported mixed fourth-quarter financial results.</p>
<p>Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share.</p>
<p>Skechers shares fell 6.9% to $59.21 on Friday.</p>
<p>Here are some other stocks moving in today&#39;s mid-day session.</p>
<h3><strong>Gainers</strong></h3>
<ul>
<li><strong>Intelligent Bio Solutions Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million.</li>
<li><strong>Minim, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday.</li>
<li><strong>Remark Holdings, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mark#NASDAQ">MARK</a>) shares climbed 33% to $0.6802.</li>
<li><strong>Kopin Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kopn#NASDAQ">KOPN</a>) jumped 30% to $2.4050.</li>
<li><strong>BioRestorative Therapies, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brtx#NASDAQ">BRTX</a>) rose 26.3% to $2.73.</li>
<li><strong>Mountain Crest Acquisition Corp. IV</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcaf#NASDAQ">MCAF</a>) gained 23% to $14.65.</li>
<li><strong>Tyra Biosciences, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tyra#NASDAQ">TYRA</a>) gained 21.8% to $15.84. Tyra Biosciences&nbsp;announced a $200 million private placement financing.</li>
<li><strong>Meta Platforms, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.</li>
<li><strong>CCSC Technology International Holdings Limited</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) gained 18.2% to $4.6099 after dipping around 82% on Thursday.</li>
<li><strong>Roma Green Finance Limited </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) gained 15.8% to $0.8697 after gaining around 5% on Thursday.</li>
<li><strong>Deckers Outdoor Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results.</li>
<li><strong>Trugolf, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trug#NASDAQ">TRUG</a>) shares jumped 14% to $1.5150 after dipping 55% on Thursday.</li>
<li><strong>Gaotu Techedu Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) gained 12.5% to $4.11.</li>
<li><strong>PropertyGuru Group Limited</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgru#NYSE">PGRU</a>) rose 11.6% to $3.57.</li>
<li><strong>NuZee, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuze#NASDAQ">NUZE</a>) gained 11.5% to $1.93.</li>
<li><strong>C3is Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 9.6% to $0.1499. S.H.N. Financial recently reported a 9.1% stake in the company.</li>
<li><strong>Applied Optoelectronics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aaoi#NASDAQ">AAOI</a>) gained 8.4% to $17.90. Applied Optoelectronics is expected to release financial results for its fourth quarter on Feb. 22, 2024.</li>
<li><strong>Amazon.com, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) shares rose 6.2% to $169.20 after the company posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter.</li>
<li><strong>Shopify Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) rose 5.9% to $81.25. Wells Fargo analyst Andrew Bauch maintained Shopify with an Overweight and raised the price target from $70 to $90.</li>
<li><strong>The Clorox Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>) shares gained 4.6% to $154.77 after the company reported better-than-expected second-quarter financial results and raised FY24 adjusted EPS guidance above estimates.</li>
</ul>
<h3><strong>Losers</strong></h3>
<ul>
<li><strong>Cingulate Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cing#NASDAQ">CING</a>) shares dipped 48.8% to $1.7206. Cingulate announced pricing of $7.5 million public offering of 3.750 million shares at $2.00 per share.</li>
<li><strong>MedAvail Holdings, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdvl#NASDAQ">MDVL</a>) fell 42.5% to $1.8068.</li>
<li><strong>Scienjoy Holding Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sj#NASDAQ">SJ</a>) dipped 37.5% to $2.10.</li>
<li><strong>ADDvantage Technologies Group, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) fell 23.6% to $0.4659. Addvantage Technologies Group said company and subsidiaries ceased operations on Jan. 26, 2024.</li>
<li><strong>FibroBiologics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) fell 23.2% to $13.63.</li>
<li><strong>GRI Bio, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) fell 21% to $1.54 after the company announced pricing of $5.5 million public offering.</li>
<li><strong>AgriFORCE Growing Systems Ltd. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) shares fell 20.7% to $0.3116. AgriFORCE Growing Systems received a Notice of Allowance for U.S. patent application 17/983,109 titled &quot;Automated Growing Systems.&quot;</li>
<li><strong>Cadrenal Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) fell 19.1% to $1.1404.</li>
<li><strong>Recruiter.com Group, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcrt#NASDAQ">RCRT</a>) declined 19% to $1.15.</li>
<li><strong>Gen Digital Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gen#NASDAQ">GEN</a>) fell 17.5% to $19.73 after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS and FY24 revenue guidance below estimates.</li>
<li><strong>WNS (Holdings) Limited</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wns#NYSE">WNS</a>) dipped 16.7% to $59.99. WNS said one of its top five customers by revenue contribution served termination notice on Jan. 31.</li>
<li><strong>Exponent, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/expo#NASDAQ">EXPO</a>) fell 15.7% to $75.77 following weak earnings.</li>
<li><strong>Hesai Group</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsai#NASDAQ">HSAI</a>) fell 14.2% to $3.45.</li>
<li><strong>Liberty Broadband Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbrda#NASDAQ">LBRDA</a>) dipped 13% to $69.39.</li>
<li><strong>Atlassian Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/team#NASDAQ">TEAM</a>) shares declined 12.8% to $222.08 after the company reported second-quarter financial results.</li>
<li><strong>Charter Communications, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chtr#NASDAQ">CHTR</a>) fell 12.6% to $333.95 following fourth-quarter results. The company missed EPS estimates and reported a loss of 62,000 residential Internet customers.</li>
<li><strong>Kiora Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) shares fell 12.4% to $0.7413. Kiora Pharmaceuticals shares jumped around 54% on Thursday after the company announced a private placement of up to roughly $45 million.</li>
<li><strong>Altice USA, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atus#NYSE">ATUS</a>) fell 8.7% to $2.2620.</li>
<li><strong>Beazer Homes USA, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bzh#NYSE">BZH</a>) declined 7.6% to $29.91 following downbeat earnings.</li>
<li><strong>Revelation Biosciences, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/revb#NASDAQ">REVB</a>) shares dipped 7.2% to $2.95. Revelation Biosciences shares fell around 64% on Thursday after the company announced the pricing of a $6.2 million offering.</li>
<li><strong>Dolby Laboratories, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dlb#NYSE">DLB</a>) declined 5.2% to $80.42 following quarterly results.</li>
<li><strong>Apple Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) shares fell 1.7% to $183.78. Apple reported better-than-expected earnings and revenue for its first quarter. However, the company reported a revenue decline in China.</li>
</ul>
<p>&nbsp;</p>
<p>Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/36910509/dow-falls-150-points-us-economy-adds-353-000-jobs-in-january"><em> Dow Falls 150 Points; US Economy Adds 353,000 Jobs In January</em></a></p>


Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<p>U.S. stocks traded mixed, with the Dow Jones falling over 100 points on Friday.</p>
<p>Shares of <strong> The Clorox Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>) shares gained during Friday&rsquo;s session after the company reported better-than-expected second-quarter financial results and raised FY24 adjusted EPS <a href="https://www.benzinga.com/quote/CLX/news">guidance above estimates</a>.</p>
<p>Clorox shares rose 4.6% to $154.77 on Friday.</p>
<p>Here are some other big stocks recording gains in today&rsquo;s session.</p>
<ul>
<li><strong>Tyra Biosciences, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tyra#NASDAQ">TYRA</a>) shares rose 21.8% to $15.84. Tyra Biosciences, announced a $200 million private placement financing.</li>
<li><strong>Meta Platforms, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) climbed 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.</li>
<li><strong>Deckers Outdoor Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>) gained 14% to $879.03 after reporting better-than-expected third-quarter financial results.</li>
<li><strong>Gaotu Techedu Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) rose 12.5% to $4.11.</li>
<li><strong>PropertyGuru Group Limited</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgru#NYSE">PGRU</a>) climbed 11.6% to $3.57.</li>
<li><strong>Nayax Ltd.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyax#NASDAQ">NYAX</a>) gained 9.2% to $26.47.</li>
<li><strong>Applied Optoelectronics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aaoi#NASDAQ">AAOI</a>) rose 8.4% to $17.90. Applied Optoelectronics is expected to release financial results for its fourth quarter on Feb. 22, 2024.</li>
<li><strong>AppLovin Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) gained 8% to $44.25.</li>
<li><strong>Clearfield, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clfd#NASDAQ">CLFD</a>) gained 7.3% to $28.03 following upbeat results.</li>
<li><strong>KB Financial Group Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kb#NYSE">KB</a>) gained 6.5% to $49.41.</li>
<li><strong>Amazon.com, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) shares surged 6.2% to $169.20 after the company posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter.</li>
<li><strong>Shopify Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) gained 5.9% to $81.25. Wells Fargo analyst Andrew Bauch maintained Shopify with an Overweight and raised the price target from $70 to $90.</li>
<li><strong>The Cigna Group</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) rose 5.7% to $324.87 after the company reported better-than-expected fourth-quarter results and issued a strong revenue outlook. The company also raised its dividend.</li>
<li><strong>Snowflake Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) gained 5% to $209.96 after Raymond James raised its price target on the stock from $190 to $223.</li>
<li><strong>LPL Financial Holdings Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpla#NASDAQ">LPLA</a>) gained 5% to $252.46 following strong earnings.</li>
<li><strong>Piper Sandler Companies</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pipr#NYSE">PIPR</a>) climbed 4.6% to $185.52 following upbeat results.</li>
<li><strong>SkyWest, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skyw#NASDAQ">SKYW</a>) gained 4.1% to $56.30. Raymond James analyst Savanthi Syth maintained SkyWest with an Outperform and raised the price target from $55 to $65.</li>
</ul>
<p>&nbsp;</p>
<p>Now Read This: <a href="https://www.benzinga.com/news/24/02/36908496/top-4-health-care-stocks-that-may-crash-this-quarter"><em> Top 4 Health Care Stocks That May Crash This Quarter</em></a></p>


CLFD

LPLA

NYAX

PIPR

SKYW

SNOW

Clorox Posts Upbeat Earnings, Joins Cigna, Deckers Outdoor And Other Big Stocks Moving Higher On Friday

Clorox shares are trading higher after the company reported better-than-expected Q2 financial results and raised FY24 adjusted EPS guidance above estimates.

<p>Shares of <strong>Meta Platforms, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) rose sharply in today&rsquo;s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.</p>
<p>The company also announced a $50 billion increase to its share repurchase authorization.</p>
<p>Meta shares climbed 16.5% to $460.02 in pre-market trading</p>
<p>Here are some other stocks moving in pre-market trading.</p>
<h3><strong>Gainers</strong></h3>
<ul>
<li><strong>CCSC Technology International Holdings Limited</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) gained 55.1% to $6.05 in pre-market trading after dipping around 82% on Thursday.</li>
<li><strong>Trugolf, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trug#NASDAQ">TRUG</a>) shares jumped 33.1% to $1.77 in pre-market trading after dipping 55% on Thursday.</li>
<li><strong>Roma Green Finance Limited </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) gained 25.2% to $0.94 in pre-market trading after gaining around 5% on Thursday.</li>
<li><strong>Jiuzi Holdings, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jzxn#NASDAQ">JZXN</a>) shares gained 20% to $0.84 in pre-market trading.</li>
<li><strong>C3is Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 18.8% to $0.1625 in pre-market trading. S.H.N. Financial recently reported a 9.1% stake in the company.</li>
<li><strong>Minim, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares rose 18.7% to $5.97 in pre-market trading after gaining more than 22% on Thursday.</li>
<li><strong>Akso Health Group </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahg#NASDAQ">AHG</a>) shares gained 13.7% to $2.55 in pre-market trading after jumping over 35% on Thursday. Akso Health recently announced its plan to make an equity investment in Deyihui, an online clinic based in China.</li>
<li><strong>The Clorox Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>) shares gained 8.1% to $159.99 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised FY24 adjusted EPS guidance above estimates.</li>
<li><strong>Amazon.com, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) shares rose 6.3% to $169.31 in pre-market trading after the company posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter.</li>
</ul>
<h3><strong>Losers</strong></h3>
<ul>
<li><strong>AgriFORCE Growing Systems Ltd. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) shares dipped 17.7% to $0.3236 in pre-market trading. AgriFORCE Growing Systems received a Notice of Allowance for U.S. patent application 17/983,109 titled &quot;Automated Growing Systems.&quot;</li>
<li><strong>Kiora Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) shares fell 14.4% to $0.7280 in pre-market trading. Kiora Pharmaceuticals shares jumped around 54% on Thursday after the company announced a private placement of up to roughly $45 million.</li>
<li><strong>GRI Bio, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) fell 13.9% to $1.68 after surging more than 20% on Thursday.</li>
<li><strong>Charles &amp; Colvard, Ltd. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cthr#NASDAQ">CTHR</a>) shares fell 13.2% to $0.35 in pre-market trading.</li>
<li><strong>Skechers U.S.A., Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/skx#NYSE">SKX</a>) declined 10.9% to $56.65 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li><strong>Cingulate Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cing#NASDAQ">CING</a>) fell 10.7% to $3.00 in pre-market trading. Cingulate named Jennifer Callahan as CFO, succeeding Lou Van Horn.</li>
<li><strong>QuantaSing Group Limited</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) shares fell 8.4% to $3.70 in pre-market trading.</li>
<li><strong>Jerash Holdings (US), Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jrsh#NASDAQ">JRSH</a>) shares declined 7.7% to $2.85 in pre-market trading. Jerash is expected to release its financial results for fiscal 2024 third quarter on Feb. 8, 2024.</li>
<li><strong>Revelation Biosciences, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/revb#NASDAQ">REVB</a>) shares dipped 7.6% to $2.94 in pre-market trading. Revelation Biosciences shares fell around 64% on Thursday after the company announced the pricing of a $6.2 million offering.</li>
<li><strong>Apple Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) shares declined 2.5% to $182.18 in pre-market trading. Apple reported better-than-expected earnings and revenue for its first quarter. However, the company reported a revenue decline in China.</li>
</ul>
<p>&nbsp;</p>
<p>Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/36904348/amazon-apple-and-3-stocks-to-watch-heading-into-friday"><em> Amazon, Apple And 3 Stocks To Watch Heading Into Friday</em></a></p>


Pre-Market Outlook

CTHR

JRSH

JZXN

Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map

Procter & Gambles misses organic sales expectations as pricing benefit fades

Procter & Gamble misses organic sales expectations as pricing benefit fades

Dividend Champion, Contender, And Challenger Highlights: Week Of April 21

Colgate-Palmolive: Improved Financials To Navigate Headwinds (Rating Upgrade)

Clorox: Attractively Valued With Good Prospects

Clorox: Still A Little Bit Too Expensive

RBC Capital analyst Nik Modi maintained a Hold rating on Clorox (CLX – Research Report) yesterday and set a price target of $143.00. The company's ...

Clorox (CLX) Receives a Hold from RBC Capital

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Rubrik</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/rbrk-stock-quote/"><strong>RBRK</strong></a></span>) &mdash; a data management software company that offers security solutions to major enterprises &mdash; just launched its initial public offering (<span>IPO</span>) today. Fundamentally, the Rubrik IPO serves as a real-time indicator regarding sustained sentiment for tech-centric new listings. Overall, RBRK stock could be a compelling speculative opportunity, although prospective buyers should recognize the risks.</p>



<p>According to <em>Bloomberg</em>, Rubrik initially planned to distribute 23 million shares for between $28 and $31 per share. However, management <a href="https://www.bloomberg.com/news/articles/2024-04-25/microsoft-backed-rubrik-exceeds-ipo-goal-to-raise-752-million?sref=0N1JmzAH&amp;embedded-checkout=true">upped the initial offering price</a> of the Rubrik IPO to $32 per share . The cloud and data security specialist also added 500,000 shares to the new listing, lifting the total amount raised from the IPO to $752 million.</p>



<p>At the IPO price, per <em>Bloomberg</em>, Rubrik would have &ldquo;a market value of about $5.6 billion, based on the outstanding shares listed in its filings.&rdquo; When factoring in stock options and restricted share units, the firm&rsquo;s fully diluted valuation comes out to more than $6.6 billion.</p>



<p>Notably, tech stalwart <strong>Microsoft</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) is a major backer of Rubrik. The company made an equity investment into the data security company in 2021. That funding cycle pushed RBRK&rsquo;s valuation to $4 billion, making the software firm a <a href="https://www.investopedia.com/terms/u/unicorn.asp">&ldquo;unicorn&rdquo;</a> prior to the Rubrik IPO.</p>



<h2>All Eyes Are on the Rubrik IPO as a Sentiment Gauge for New Listings</h2>



<p>While the Rubrik IPO has not been as popular as the <strong>Reddit</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/"><strong>RDDT</strong></a>) IPO earlier this year, it should still serve as a litmus test regarding the sustained interest for new listings. As <em>Fast Company</em> notes, <a href="https://www.fastcompany.com/91112976/rubrik-ipo-stock-price-today-microsoft-backed-nyse">encouraging signs exist</a> when it comes to the U.S. IPO market:</p>




<p>&ldquo;Although the number of public offerings in the first quarter of 2024 was similar to the same quarter a year ago, the deals were larger. EY reports that proceeds for the period tripled, with seven deals raising more than $500 million, compared to only one deal during the first quarter of 2023.&rdquo;</p>




<p><em>Bloomberg</em> corroborates this optimistic backdrop for new listings. &ldquo;Since the beginning of the year, companies have raised more than $12.2 billion on US exchanges, more than twice as much as in the same period in 2023,&rdquo; reported the outlet. <em>Bloomberg </em>added that &ldquo;two dozen offerings over $100 million were completed this year, spanning sectors from sporting goods to safety testing.&rdquo;</p>



<h2>Should You Buy RBRK Stock?</h2>



<p>On one hand, RBRK stock is compelling because of the data security angle. Increasingly, both individuals and enterprises are finding the internet to be a treacherous place. Last year, <strong>Clorox</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/clx-stock-quote/"><strong>CLX</strong></a>) made news due to a <a href="https://investorplace.com/2023/10/clorox-clx-stock-just-hit-a-new-52-week-low/">cyberattack that caused significant financial harm</a>. Therefore, many businesses are likely still looking for systems to protect themselves.</p>



<p>On the other hand, though, Rubrik disclosed a net loss of $354 million for the fiscal year ended Jan. 31. That&rsquo;s despite growing its subscription-based revenue by 47%. Of course, it&rsquo;s not unusual for tech firms to post red ink. But investors may want to consider the broader economic environment and projected sentiment for risk-on assets before making a decision to buy RBRK stock.</p>



<p><em>On the date of publication, Josh Enomoto did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/should-you-buy-the-rubrik-rbrk-stock-ipo/">Should You Buy the Rubrik (RBRK) Stock IPO?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Should You Buy the Rubrik (RBRK) Stock IPO?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The stock market has taken a concerning dive in recent weeks, and this downward trajectory may persist&nbsp;going forward, so it&rsquo;s time to consider stocks to buy before a market crash. </p>



<p>Many investors&nbsp;are gripped&nbsp;by fears that interest rates will remain elevated for an extended period while inflation proves stubbornly resistant to coming down from 40-year highs. These anxieties have only intensified following the <a href="https://www.barrons.com/livecoverage/us-gdp-first-quarter-report">latest GDP report</a>,&nbsp;highlighting&nbsp;an economic slowdown. Specifically, inflation-adjusted gross domestic product grew at a disappointing annualized rate of just 1.6% &mdash; far below expectations of 2.2% growth and a marked deceleration from previous quarters.</p>



<p>Adding to the unease is the fact that we&rsquo;ve experienced a sustained market rally for many months.&nbsp;It&rsquo;s somewhat reminiscent of the frenzied run-up in 2021. This confluence of factors sets the stage for a sizable market correction in the coming months as gravity finally takes hold.</p>



<p>Consequently, it may be prudent for investors to take some profits off the table and shift capital into more stable stocks before redeploying into beaten-down growth plays at cheaper valuations. It&rsquo;s time to make tactical portfolio adjustments and determine the stocks to buy before a market crash.</p>



<h2>Costco (COST)</h2>



<div><img width="300" height="150" src="https://investorplace.com/wp-content/uploads/2017/05/costco-wholesale-corporation-cost-ipsize-300x150.jpg" alt="Costco Stock May Be the Market&rsquo;s Top Recession Pick"><div>Source: Shutterstock</div></div><p><strong>Costco</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cost-stock-quote/"><strong>COST</strong></a>) is a company that operates a chain of membership-only big-box warehouse club retail stores. It sells&nbsp;various&nbsp;products, including electronics, computers, furniture, outdoor living items, appliances and jewelry. This company has very sticky demand.&nbsp;This&nbsp;is&nbsp;mostly due&nbsp;to Costco&rsquo;s membership model.</p>



<p>It costs consumers less to buy from Costco due to its bulk selling strategy&nbsp;and&nbsp;membership program.&nbsp;The stock has seen such strong performance in recent months: inflation squeezes people. Costco is up 46% in the past year. This sort of price performance for a retail company is&nbsp;very impressive.</p>



<p>Of course, I do not expect it to keep going up like this&nbsp;soon, but it can be a safe long-term holding to hold your portfolio together during the next downturn. Costco&nbsp;is expected&nbsp;to keep growing EPS at 10% annually and&nbsp;revenue growth at 6.5% annually on average in the coming years. It also yields a modest 0.64% in dividends.</p>



<h2>Coca-Cola (KO)</h2>



<div><img width="300" height="168" src="https://investorplace.com/wp-content/uploads/2014/11/coca-cola-life-ko-stock-300x168.jpg" alt="ko stock coca cola life"><div>Source: Coca-Cola</div></div><p>There is no need to explain <strong>Coca-Cola</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ko-stock-quote/"><strong>KO</strong></a>) or what it does to anyone, no matter where they might be from. This company arguably has the most recognizable brand name on the planet. The demand here has been exceptionally sticky through many downturns and recessions. Coca-Cola&rsquo;s products are discretionary only in name.</p>



<p>Many people can&rsquo;t imagine a meal without Coca-Cola, so I see it as more of a staple. It is hard to imagine the company to take a demand hit even during a&nbsp;bad&nbsp;downturn.</p>



<p>Don&rsquo;t expect much gains here either,&nbsp;as&nbsp;the stock has been flat for the past year. However, stability is what matters during a downturn.&nbsp;Coca-Cola has an attractive 3.14% dividend yield you can sit on while the storm passes.&nbsp;Analysts <a href="https://seekingalpha.com/symbol/KO/earnings/estimates">expect mid-single-digit sales growth</a> and slightly higher EPS growth in the coming years.</p>



<h2>Ares Capital (ARCC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/arcc-stock-1-300x169.jpg" alt="Ares Capital (ARCC) logo on its webpage"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p>This pick may surprise many&nbsp;as it is not a big or well-established company. However, it has very attractive and stable financials. <strong>Ares Capital Corporation</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/arcc-stock-quote/"><strong>ARCC</strong></a>) is a <strong>Business Development Company</strong> (<a href="https://investorplace.com/stock-quotes/bdc-stock-quote/"><strong>BDC</strong></a>) that provides financing solutions to middle-market companies. It offers funding in the form of loans and private equity. Ares Capital has a well-diversified portfolio with lower exposure to some of the riskiest industries&nbsp;than&nbsp;its peers.</p>



<p>Moreover, the company primarily lends to underserved midsize businesses in the U.S. and benefits as high interest rates help it earn even higher returns on its loans. The stock has delivered 16% in gains in the past year,&nbsp;and&nbsp;I see further stable growth&nbsp;down the line. Of course, financial firms will take a hit during a downturn, but I do not think&nbsp;Ares Capital will be hit&nbsp;too badly.&nbsp;It has learned from 2008, recovered&nbsp;very well from the 2020 downturn, and&nbsp;weathered the 2022 correction quite well.</p>



<p>Warren Buffett&rsquo;s New England Asset Management also has a stake in the stock, which boosts my conviction here.</p>



<h2>Procter &amp; Gamble (PG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/shutterstock_1073950868-300x169.png" alt="Procter &amp; Gamble Union Distribution Center. P&amp;G is an American Multinational Consumer Goods Company"><div>Source: Jonathan Weiss / Shutterstock.com</div></div><p>The company makes many things people use every day. They make things like shampoo, toothpaste, diapers and cleaning products. It has very sticky demand and is one of the best consumer stocks you can buy to add more ballast to your portfolio. It is hard to find an article on stable stocks to buy before a market crash without <strong>Procter &amp; Gamble</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pg-stock-quote/"><strong>PG</strong></a>) in it. The stock has delivered 54% gains in the past five years and has been on a stable growth trajectory.</p>



<p>Analysts <a href="https://seekingalpha.com/symbol/PG/earnings/estimates">expect revenue growth of around 4% annually</a> going forward, along with EPS growth of around 6%&nbsp;on average. Paying 25 times forward earnings is pretty reasonable, considering you&rsquo;re also getting a 2.47% dividend yield on the stock and an 18% net margin, better than 92% of the company&rsquo;s peers.</p>



<h2>Clorox (CLX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/clx1600-300x169.jpg" alt="Clorox bleach bottles lined up on a store shelf."><div>Source: TY Lim / Shutterstock.com</div></div><p><strong>Clorox</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/clx-stock-quote/"><strong>CLX</strong></a>) is another very well-known brand, and why this company&rsquo;s demand is so sticky does not need to be explained. It&rsquo;s another &ldquo;boring&rdquo; pick to shift your profits into to weather the storm. The stock has essentially been flat over the past five years except for the increase in share price in 2021, which was reversed quickly. The current share price makes it more or less fairly valued. You can just buy the stock and sit on its 3.25% dividend yield.</p>



<p>The company also plans to increase advertising moving forward. According to management, the company&rsquo;s advertising spending as a percentage of sales is expected to increase to about 11% in fiscal year 2024 vs from 9% last year to boost sales more. It has a <a href="https://www.gurufocus.com/stock/CLX/summary">fair amount of debt at $3.1 billion</a> that it pays interest on, so rate cuts going forward should also help growth moving forward.</p>



<p>Regardless, any change in growth is unlikely to be notable. This company is very stable, and I expect the shares to remain stable. There shouldn&rsquo;t be any rapid moves to the upside or the downside, barring a major recession, in which case it shouldn&rsquo;t decline too much.</p>



<h2>Kimberly-Clark (KMB)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/05/kmbmsn-300x165.jpg" alt="Kimberly Clark Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>)"><div>Source: Shutterstock</div></div><p><strong>Kimberly-Clark</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/kmb-stock-quote/"><strong>KMB</strong></a>) is a competitor to Procter &amp; Gamble. This company makes consumer goods in the personal care sector. However, there are some differences between the two. For example, Procter &amp; Gamble has many brands and products. Also, Procter &amp; Gamble has been able to grow sales and keep costs down better than Kimberly-Clark. This has helped Procter &amp; Gamble stay strong, even when times are tough.</p>



<p>However, it is important to remember that both companies are very stable and can weather downturns excellently compared to most other companies. The stock&rsquo;s performance has not been as good as Procter &amp; Gamble&rsquo;s, but that is somewhat made up by the higher dividend yield at 3.58%. HSBC recently <a href="https://www.investing.com/news/company-news/kimberly-clark-stock-target-raised-on-margin-recovery-93CH-3394769">raised the stock price target</a> for shares of Kimberly Clark to $150 from $146, citing the potential for a margin recovery and benefits from a cost savings program at Kimberly Clark.</p>



<h2>Air Canada (ACDVF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/air-canada-ac-1600-300x169.jpg" alt="image of air canada airplane"><div>Source: Vytautas Kielaitis / Shutterstock</div></div><p>Airline companies are rarely the most stable and rarely discussed when discussing stocks to buy before a market crash. However, I believe you should look deeper into <strong>Air Canada</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/acdvf-stock-quote/"><strong>ACDVF</strong></a>), as the stock has been beaten down quite a lot and is likely to recover in the coming years as rates come down. The stock has been trading flat at bargain-basement prices, and I do not think it can go down much from here, even during a downturn.</p>



<p>Gurufocus <a href="http://www.gurufocus.com/stock/ACDVF/summary">estimates its fair price value to be</a> $30. You&rsquo;re only paying 3.4 times earnings for the stock. Moreover, the company is paying $150-170 million per quarter on interest expenses, which it can save once rates come down.</p>



<p>It does have a solid cash position at $6.4 billion against $10.3 billion of debt, but the interest pressure on earnings still makes it look bad to Wall Street. Once rates come down, I believe Air Canada can outperform the market while having a margin of safety as earnings grow.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/shift-your-gains-to-these-7-stocks-before-the-market-takes-a-dive/">Shift Your Gains to These 7 Stocks Before the Market Takes a Dive</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Shift Your Gains to These 7 Stocks Before the Market Takes a Dive

ACDVF

ADBE

ADSK

ARCC

BIIB

BMYMP

CHRW

CMCSA

COST

CSCO

CTVA

DGICA

DGICB

ERIE

ETSY

FAST

FBNC

GILD

HBCP

HFBL

INGR

JOUT

KVUE

LKFN

MDLZ

MKTX

MSFT

OFLX

ORCL

RBRK

RDDT

SBUX

SPFI

STAG

VALU

VEEV

VRSN

VRTS

Press Releases

General Mills Elects Two New Board Members

Earnings

Clorox Reports Q2 Fiscal Year 2024 Results, Updates Outlook

Clorox to Present at 2024 CAGNY Conference

Commodities

The Clorox Company Named Barron's Most Sustainable U.S. Company for Second Year in a Row

Dividends

Clorox Declares Regular Quarterly Dividend of $1.20 Per Share

Burt's Bees® Showcases Clinical Efficacy of Aloe and Prebiotic Containing Products in Addressing Common Skin Concerns

Clorox Divests its Operations in Argentina, Uruguay and Paraguay

Pine-Sol® Announces Reformulated Multi-Surface Cleaners, Delivering 2x the Cleaning Power